Radiation plus chemo-immunotherapy for colon cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of colon or rectal cancer called MSS or pMMR adenocarcinoma (these are specific genetic features).
- The rectal cancer must be at a certain stage (T3–4 or N1–2) and have spread to the liver but nowhere else.
- You cannot have had any previous cancer treatment like chemotherapy, radiation, or immunotherapy.
- You need to be in generally good health, able to care for yourself (ECOG score 0 or 1), and have adequate heart, liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for stomach or colon cancer that has spread to the lining of the abdomen. It combines low-dose radiation with a type of immunotherapy called NIPS to help your body fight the cancer. The goal is to see if this combination can shrink the tumors and improve outcomes.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests a combination therapy that includes an immunotherapy drug (called anti-PD-1) for people with rectal cancer that has spread to the liver or lungs. The goal is to see if this treatment can help shrink or control the cancer, and it may be an option if you haven't had treatment yet.
This trial tests whether giving low-dose radiation to liver tumors along with immunotherapy can help people with certain advanced cancers that have spread to the liver. It may improve how well the treatment works for people whose cancer has stopped responding to earlier treatments.
This trial tests combining focused radiation (SBRT) with immunotherapy for colorectal cancer that has spread to the liver or lungs. The goal is to see if this combination can shrink tumors and improve control of the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.